<DOC>
	<DOCNO>NCT02771860</DOCNO>
	<brief_summary>This randomize , double blind placebo control one-site proof-of-concept study subject erosive osteoarthritis ( OA ) interphalangeal ( IP ) finger joint . A total 100 subject enrol study : 48 week placebo control double-blind phase denosumab 60mg every 12 week , follow 48-week open-label phase subject receive denosumab .</brief_summary>
	<brief_title>RANKL-blockade Treatment Erosive Osteoarthritis ( OA ) Interphalangeal Finger Joints</brief_title>
	<detailed_description>Investigational therapy : denosumab 60mg subcutaneous injection every 12 week . All subject receive Calcium/vit D supplementation . Efficacy objective : The primary objective ass effect denosumab reduction radiographic erosive progression use GUSS ( Ghent University Score System ) . The secondary objective ass effect denosumab reduction radiographic erosive progression define diminish appearance new erosive IP finger joint . The exploratory objective mainly assess effect denosumab clinical variable , well ultrasonography DEXA ( dual energy x-ray absorptiometry ) parameter .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>• Subjects hand OA suffer transient inflammatory attack interphalangeal finger joint characteristic term 'inflammatory ' 'erosive ' hand OA . Subjects hand OA show inflammatory sign , either clinically ultrasonographically , interphalangeal finger joint . Subjects hand OA least 1 interphalangeal finger joint typical appearance Xrays ' J ' ' E ' phase joint define criterion mention . Subjects hand OA least 1 interphalangeal finger joint ' J ' ' E ' phase present palpable swell . • Patients know hypersensitivity mammalianderived drug preparation . Patients clinically significant hypersensitivity component Prolia . Current and/or Prior treatment investigational agent within 90 day , five halflives product , whichever longer . Previous administration denosumab clinical trial others ( e.g . commercial use ) . Vitamin D deficiency [ 25 ( OH ) vitamin D level &lt; 20 ng/mL ( &lt; 49.9 nmol/L ) ] . Possibility replenishment rescreening . Subjects current hypo hypercalcemia ( normal serum calcium level : 8.510.5 mg/dl 2.122.62 mmol/L ) . Patients currently bisphosphonate ( BP ) treatment use oral BPs within 12 month study enrollment intravenous BPs strontium ranelate within 5 year study enrollment Prior use chondroprotective drug within 90 day e.g . chondroitin sulfate , glucosamine , avocadosoybean unsaponifiables , tetracyclins , corticosteroid . Prior use immunomodulating drug possible effect proinflammatory cytokine metabolism within 90 day a.o . corticosteroid , methotrexate , sulfasalazine , leflunomide , DPenicillin , antimalarial , cytotoxic drug , TNF ( tumor necrosis factor ) block agent . History drug alcohol abuse last year . Patients suffer chronic inflammatory rheumatic disease ( e.g . rheumatoid arthritis , spondylarthropathy , psoriatic arthritis , gout , chondrocalcinosis autoimmune disease , e.g . systemic lupus erythematosus ) . History cancer lymphoproliferative disease successfully completely treat squamous cell basal cell carcinoma skin cervical dysplasia , recurrence within last two year . History Solid Organ Bone Marrow Transplant . Comorbidities : significant renal function impairment ( glomerular filtration &lt; 30 ml/min/1.73m2 &lt; 50 % normal value ) , uncontrolled diabetes , unstable ischemic heart disease , congestive heart failure ( NYHA III , IV ) , uncontrolled hypo hyperparathyroidism , active inflammatory bowel disease , malabsorption , liver failure chronic hepatic disease ( serum AST ( aspartate aminotransferase ) / ALT ( alanine aminotransferase ) level 3 time normal ) , recent stroke ( within three month ) , chronic leg ulcer condition ( e.g , . indwell urinary catheter ) , opinion investigator , would put subject risk participation protocol . Subject kind disorder compromise ability subject give write informed consent and/or comply study procedure . Patient pregnant planning pregnancy ; female subject childbearing age , must use valid mean contraception study 9 month last dose study medication . For male partner childbearing potential : subject refuse use 1 effective method contraception duration study 10 month last dose study medication . Female subject breastfeed . History osteonecrosis jaw , and/or recent ( within 3 month ) tooth extraction unhealed dental surgery ; plan invasive dental work study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>denosumab</keyword>
	<keyword>RANKL-blockade</keyword>
</DOC>